← 返回

IGF2BP3 促进免疫逃逸并预示头颈部鳞状细胞癌不良预后

英文原题:IGF2BP3 promotes immune evasion and predicts poor prognosis in head and neck squamous cell carcinoma.

查看英文原题

IGF2BP3 promotes immune evasion and predicts poor prognosis in head and neck squamous cell carcinoma.

PubMed 2026/03/24(内容时间) Transl Cancer Res Q3 · IF 2.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

IGF2BP3 在 HNSCC 中过表达,并与晚期分期、不良预后和免疫抑制性免疫景观相关。IGF2BP3 是一个有前景的诊断和预后生物标志物,并可能构成 HNSCC 的潜在治疗靶点。

研究思路结论见上方概要

头颈部鳞状细胞癌(HNSCC)是一种常见的恶性肿瘤,死亡率高且预后生物标志物有限。RNA结合蛋白胰岛素样生长因子2 mRNA结合蛋白3(IGF2BP3)识别N6-甲基腺苷(m6A)并促进多种癌症的肿瘤进展,但其在HNSCC中的预后价值和免疫学作用仍不清楚。本研究旨在探索IGF2BP3在HNSCC发病机制中的作用,研究其作为可靠诊断和预后生物标志物的潜力,并评估其作为新型免疫治疗靶点的适用性,以改善HNSCC患者的临床结局。

利用癌症基因组图谱(TCGA)和基因型-组织表达(GTEx)数据集分析了IGF2BP3表达及其与临床病理特征和生存的关联。采用受试者工作特征(ROC)曲线和多因素Cox回归评估其诊断和预后价值。通过cBioPortal鉴定共表达基因,随后进行基因本体论(GO)、京都基因与基因组百科全书(KEGG)和蛋白质-蛋白质相互作用(PPI)分析。使用单样本基因集富集分析(ssGSEA)估计免疫细胞浸润。通过小干扰RNA(siRNA)敲低、CCK-8(CCK-8)增殖实验、伤口愈合实验和Transwell迁移/侵袭实验在SCC-25细胞中验证IGF2BP3的功能作用。

IGF2BP3 messenger RNA (mRNA) 和蛋白在 HNSCC 组织中较正常对照显著上调(P<0.001)。ROC 分析得出曲线下面积(AUC)为 0.809 [95% 置信区间 (CI):0.753-0.866],表明具有良好的诊断性能。IGF2BP3 高表达与晚期临床分期相关,并在多因素 Cox 分析中独立预测更差的总生存期。富集分析提示 IGF2BP3 相关基因参与代谢重编程和 RNA 结合蛋白网络。IGF2BP3 表达与 Th2 细胞呈正相关,与细胞毒性 T 细胞和自然杀伤 (NK) 细胞呈负相关,表明存在免疫抑制性肿瘤微环境。在功能上,IGF2BP3 敲低在体外显著抑制 SCC-25 细胞增殖、迁移和侵袭(均 P<0.01)。

展开英文摘要原文

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy with high mortality and limited prognostic biomarkers. The RNA-binding protein insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3) recognizes N6-methyladenosine (m6A) and promotes tumor progression in multiple cancers, but its prognostic value and immunological role in HNSCC remain unclear. This study aims to explore the role of IGF2BP3 in the pathogenesis of HNSCC, investigate its potential as a reliable diagnostic and prognostic biomarker, and assess its applicability as a novel immunotherapeutic target, with the goal of improving clinical outcomes for patients with HNSCC.

IGF2BP3 expression and its association with clinicopathological features and survival were analyzed using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Receiver operating characteristic (ROC) curves and multivariate Cox regression were used to evaluate its diagnostic and prognostic value. Co-expressed genes were identified via cBioPortal, followed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) analyses. Immune cell infiltration was estimated using single-sample gene set enrichment analysis (ssGSEA). The functional role of IGF2BP3 was validated in SCC-25 cells using small interfering RNA (siRNA) knockdown, Cell Counting Kit-8 (CCK-8) proliferation assays, wound-healing assays, and Transwell migration/invasion assays.

IGF2BP3 messenger RNA (mRNA) and protein were significantly upregulated in HNSCC tissues compared with normal controls (P<0.001). ROC analysis yielded an area under the curve (AUC) of 0.809 [95% confidence interval (CI): 0.753-0.866], indicating good diagnostic performance. High IGF2BP3 expression was associated with advanced clinical stage and independently predicted worse overall survival in multivariate Cox analysis. Enrichment analyses suggested that IGF2BP3-related genes were involved in metabolic reprogramming and RNA-binding protein networks. IGF2BP3 expression correlated positively with Th2 cells and negatively with cytotoxic T and natural killer (NK) cells, indicating an immunosuppressive tumor microenvironment. Functionally, IGF2BP3 knockdown significantly inhibited SCC-25 cell proliferation, migration, and invasion in vitro (all P<0.01).

IGF2BP3 is overexpressed in HNSCC and is associated with advanced stage, unfavorable prognosis, and an immunosuppressive immune landscape. IGF2BP3 represents a promising diagnostic and prognostic biomarker and may constitute a potential therapeutic target in HNSCC.

论文信息

作者
Lu W、Zhang G、Ding Y、Liao F、Luo Y、Sui Y、Zhang X、Wu P
单位
Department of Otolaryngology-Head and Neck Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.Hong Kong
期刊
Translational cancer research2026 Apr 30
原文标识
PubMed 42180918 · DOI 10.21037/tcr-2025-1-2742